Improving the Postmarket Surveillance of Total Joint Arthroplasty Devices
Author Information
Author(s): Mahomed Nizar N, Syed Khalid, Sledge Clement B., Brennan Troyen A, Liang Matthew H
Primary Institution: University of Toronto
Hypothesis
To evaluate the FDA’s approval process and postmarket surveillance strategies for THR devices.
Conclusion
Current FDA premarket approval and postmarket surveillance strategies fail to provide information for evidence-based selection of THR devices.
Supporting Evidence
- Over 95% of hip replacement devices were approved without requiring clinical data on safety or effectiveness.
- The FDA's postmarket surveillance system captured only 6% of reportable THR device-related problems.
- Only 15% of approved THR devices had published data on clinical outcomes.
- Attempts to obtain clinical data from manufacturers were largely unsuccessful.
Takeaway
The study found that many hip replacement devices were approved without proper safety checks, and most problems with these devices go unreported.
Methodology
The study analyzed FDA approval data and postmarket surveillance reports for total hip replacement devices from 1976 to 1995.
Potential Biases
The reliance on voluntary reporting for adverse events may lead to underreporting and bias in the data.
Limitations
The study faced challenges in obtaining complete data from manufacturers and highlighted the low reporting rates of device-related problems.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website